Picture loading failed.

Pre-Made Lenvervimab biosimilar, Whole Mab: Anti-HBV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lenvervimab (INN development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-302-1mg 1mg 3090
GMP-Bios-ab-302-10mg 10mg Inquiry
GMP-Bios-ab-302-100mg 100mg Inquiry
GMP-Bios-ab-302-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Lenvervimab biosimilar, Whole Mab: Anti-HBV therapeutic antibody
INN Name Lenvervimab
TargetHBV
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesGreen Cross;GC Pharma;AbbVie
Conditions Approvedna
Conditions ActiveHepatitis B
Conditions Discontinuedna
Development Techna